Suppr超能文献

GSK-3突变体的表达、特性及其对完整细胞中β-连环蛋白磷酸化的影响

Expression and characterization of GSK-3 mutants and their effect on beta-catenin phosphorylation in intact cells.

作者信息

Hagen Thilo, Di Daniel Elena, Culbert Ainsley A, Reith Alastair D

机构信息

Systems Research-Kinase Biology Discovery Research, GlaxoSmithKline Pharmaceuticals, Harlow, Essex, CM19 5AD, United Kingdom.

出版信息

J Biol Chem. 2002 Jun 28;277(26):23330-5. doi: 10.1074/jbc.M201364200. Epub 2002 Apr 19.

Abstract

Glycogen synthase kinase-3 (GSK-3) is a serine-threonine kinase that is involved in multiple cellular signaling pathways, including the Wnt signaling cascade where it phosphorylates beta-catenin, thus targeting it for proteasome-mediated degradation. Unlike phosphorylation of glycogen synthase, phosphorylation of beta-catenin by GSK-3 does not require priming in vitro, i.e. it is not dependent on the presence of a phosphoserine, four residues C-terminal to the GSK-3 phosphorylation site. Recently, a means of dissecting GSK-3 activity toward primed and non-primed substrates has been made possible by identification of the R96A mutant of GSK-3beta. This mutant is unable to phosphorylate primed but can still phosphorylate unprimed substrates (Frame, S., Cohen, P., and Biondi R. M. (2001) Mol. Cell 7, 1321-1327). Here we have investigated whether phosphorylation of Ser(33), Ser(37), and Thr(41) in beta-catenin requires priming through prior phosphorylation at Ser(45) in intact cells. We have shown that the Arg(96) mutant does not induce beta-catenin degradation but instead stabilizes beta-catenin, indicating that it is unable to phosphorylate beta-catenin in intact cells. Furthermore, if Ser(45) in beta-catenin is mutated to Ala, beta-catenin is markedly stabilized, and phosphorylation of Ser(33), Ser(37), and Thr(41) in beta-catenin by wild type GSK-3beta is prevented in intact cells. In addition, we have shown that the L128A mutant, which is deficient in phosphorylating Axin in vitro, is still able to phosphorylate beta-catenin in intact cells although it has reduced activity. Mutation of Tyr(216) to Phe markedly reduces the ability of GSK-3beta to phosphorylate and down-regulate beta-catenin. In conclusion, we have found that the Arg(96) mutant has a dominant-negative effect on GSK-3beta-dependent phosphorylation of beta-catenin and that targeting of beta-catenin for degradation requires prior priming through phosphorylation of Ser(45).

摘要

糖原合酶激酶-3(GSK-3)是一种丝氨酸-苏氨酸激酶,参与多种细胞信号通路,包括Wnt信号级联反应,在该反应中它使β-连环蛋白磷酸化,从而使其靶向蛋白酶体介导的降解。与糖原合酶的磷酸化不同,GSK-3对β-连环蛋白的磷酸化在体外不需要引发,即它不依赖于在GSK-3磷酸化位点C端四个残基处存在磷酸丝氨酸。最近,通过鉴定GSK-3β的R96A突变体,使得剖析GSK-3对引发和未引发底物的活性成为可能。该突变体无法使引发的底物磷酸化,但仍能使未引发的底物磷酸化(弗雷姆,S.,科恩,P.,以及比昂迪,R. M.(2001年)《分子细胞》7卷,1321 - 1327页)。在此,我们研究了在完整细胞中β-连环蛋白中Ser(33)、Ser(37)和Thr(41)的磷酸化是否需要通过Ser(45)处的预先磷酸化来引发。我们已经表明,Arg(96)突变体不会诱导β-连环蛋白降解,反而会使其稳定,这表明它在完整细胞中无法使β-连环蛋白磷酸化。此外,如果β-连环蛋白中的Ser(45)突变为Ala,β-连环蛋白会明显稳定,并且在完整细胞中野生型GSK-3β对β-连环蛋白中Ser(33)、Ser(37)和Thr(41)的磷酸化会受到抑制。另外,我们已经表明,在体外缺乏使Axin磷酸化能力的L128A突变体,尽管其活性降低,但在完整细胞中仍能使β-连环蛋白磷酸化。将Tyr(216)突变为Phe会显著降低GSK-3β使β-连环蛋白磷酸化并下调β-连环蛋白的能力。总之,我们发现Arg(96)突变体对GSK-3β依赖的β-连环蛋白磷酸化具有显性负效应,并且β-连环蛋白靶向降解需要通过Ser(45)的磷酸化进行预先引发。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验